ArticleIn vivo (Athens, Greece)
Partial Splenic Embolization for Portal Hypertension Exacerbation During Atezolizumab/Bevacizumab Combination Therapy in Unresectable Hepatocellular Carcinoma.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Electronic health record dynamic features for in-hospital death among chronic kidney disease patients.Scientific reports · 2026Article
- From Splenectomy to Partial Splenic Embolization, Which is Better for Hereditary Spherocytosis?Journal of blood medicine · 2026Review
- Effect of Partial Splenic Embolization on Immune Environment and Hepatic Function in Cirrhosis Patients With Portal Hypertension.In vivo (Athens, Greece)Article
- Response-survival Association Differs by Hepatic Reserve in Unresectable HCC Receiving Atezolizumab Plus Bevacizumab.Cancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimThe combination of atezolizumab and bevacizumab is the standard treatment for hepatocellular carcinoma (HCC). However, cases of portal hypertension (PHT) have been reported with atezolizumab/bevacizumab combination therapy. Splenomegaly caused by PHT may disrupt the immune environment and increase the risk of therapeutic failure with this combination therapy. Partial splenic embolization (PSE) is a treatment option for splenomegaly; however, the usefulness of PSE for PHT during atezolizumab/bevacizumab combination therapy is unclear. This study investigated the effect of PSE on the immune environment in a patient with splenomegaly caused by exacerbation of PHT during atezolizumab/bevacizumab combination therapy for HCC. PATIENTS AND
methodsOf the 56 patients with unresectable HCC treated with atezolizumab/bevacizumab, four with splenomegaly and progressive disease (PD) underwent PSE.
resultsPHT during atezolizumab/bevacizumab combination therapy led to a mean enlargement of the splenic size of 142.7%, an increase in the neutrophil-lymphocyte ratio (NLR), a decrease in lymphocyte counts, and a decrease in platelet counts. PSE increased platelet counts and lymphocyte counts, and decreased the NLR compared with pre-PSE levels. Atezolizumab/bevacizumab combination therapy, which caused PD due to PHT, resulted in a non-PD state with continued treatment after PSE.
conclusionIn patients with PHT receiving atezolizumab/bevacizumab combination therapy, PSE promotes recovery from leukopenia and thrombocytopenia. Furthermore, PSE treatment may also induce host immune activation and boost immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.